Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Stock Information for Forte Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Forte Biosciences Inc.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Forte Biosciences, Inc. Announces Results and Provides Update
Forte Biosciences Announces Pricing of $75 Million Public Offering
Forte Biosciences Announces Proposed Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.